Carina Biotech
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
AUD250k | Grant | ||
AUD750k | Grant | ||
* | AUD5.4m | Early VC | |
* | $5.2m Valuation: $27.0m | Early VC | |
Total Funding | €8.5m |
Related Content
Recent News about Carina Biotech
EditCarina Biotech is an Australian clinical-stage immunotherapy company focused on researching and developing chimeric antigen receptor T cell (CAR T) therapies to treat solid cancers. CAR T therapy is a groundbreaking treatment that harnesses a patient's immune system to combat cancer. Carina Biotech operates in the biotechnology and healthcare market, primarily serving patients with colorectal and ovarian cancers. The company collaborates with various industry participants, clinicians, healthcare providers, and research organizations to advance its CAR T programs. Carina Biotech generates revenue through partnerships, research grants, and potential future commercialization of its therapies. The company is actively involved in presenting its research findings at major industry conferences, attracting interest from pharmaceutical investors.
Keywords: CAR T therapy, immunotherapy, solid cancers, colorectal cancer, ovarian cancer, biotechnology, healthcare, clinical-stage, research, collaboration.